News

Important Safety Alert The MHRA has issued a safety alert regarding a significant drug interaction between warfarin and tramadol. This combination can cause harmful interactions that elevate the International Normalised Ratio (INR) and result in severe bruising, bleeding, and in some cases, fatal outcomes. Key Points Warfarin and tramadol together increase the risk of serious […]

MHRA Safety Update: May 2024 Recalls and Letters The MHRA has published a summary of letters and safety notifications issued to healthcare professionals during May 2024. This update covers recent medicines and medical device alerts that may affect your clinical practice and patient care. What You Need to Know The MHRA regularly communicates important safety […]

MHRA Safety Update: Topical Steroids The MHRA has issued an important reminder about topical steroid safety, with new labelling coming to products in the coming months. While these medications are safe and effective for managing inflammatory skin conditions, prolonged use—especially at high potency—carries significant risks that all clinicians and responders should be aware of. Key […]

April 2024 MHRA Safety Communications The MHRA has published a comprehensive summary of letters and safety notifications issued to healthcare professionals during April 2024. This update covers recent medicine recalls and device safety information relevant to clinical practice across all care settings. Key Points This monthly summary consolidates important safety communications that may affect your […]

Key Safety Update on Finasteride The MHRA has issued a reminder about important side effects associated with finasteride, a commonly prescribed medication for male pattern baldness and benign prostatic hyperplasia. A new patient alert card is being introduced to raise awareness among men taking this drug. What You Need to Know Finasteride carries a documented […]

Important Safety Reminder The MHRA has issued a reminder about the risk of neuropsychiatric reactions associated with montelukast use. This alert applies to all patient groups, including children and adolescents, and reinforces previous safety communications on this issue. Key Safety Points Neuropsychiatric reactions have been reported in patients taking montelukast Reported effects include sleep disorders, […]

March 2024 MHRA Safety Communications The MHRA has published a summary of letters and notifications issued to healthcare professionals during March 2024 concerning medicines and medical devices. This update consolidates important safety information relevant to clinical practice across primary and secondary care. Key Points Multiple safety communications were issued in March 2024 affecting various medicines […]

February 2024 MHRA Safety Notifications The MHRA has published a summary of letters and notifications issued to healthcare professionals during February 2024. This update covers important safety information on medicines and medical devices that may affect your clinical practice and patient care. What You Need to Know Regular safety alerts from the MHRA help ensure […]

Codeine Linctus Now Prescription-Only The MHRA has reclassified codeine linctus (codeine oral solutions) from a general sales list (GSL) medicine to a prescription-only medicine (POM). This change follows a public consultation and reflects updated safety considerations for this commonly used cough suppressant. What You Need to Know Codeine linctus can no longer be supplied over-the-counter […]

MHRA Drug Safety Update The MHRA has issued a safety alert regarding very rare reports of serious neurological conditions associated with pseudoephedrine use. What You Need to Know Very rare cases of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) have been reported in patients taking pseudoephedrine. While these events are uncommon, […]